title: [Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke].
abstract: Platelet aggregation was examined in 43 patients after ischemic stroke and in 16 healthy subjects using multiparametric aggregation index (MAI). The value of MAI was significantly higher in stroke patients (3.15 in patients and 0.92 l/mumol in controls, p < 0.0001). Patients who had increased MAI (n = 26) were treated with a daily dose of 100 mg acetilsalicylic acid (ASA). Platelet activity was measured before and on the 7th and 28th day of treatment measuring three parameters: MAI, spontaneous dysaggregation and collagen induced aggregation. All 3 methods showed a significant decrease in platelet aggregation on the 7th day of treatment, but further changes were not found on the 28th day. Serum levels of thromboxane-A2 (TXA2) and prostacycline (PGI2) metabolites (TXB2 and 6-keto-prostaglandin-F1 alpha) were determined before and on the 28th day of treatment. The effect of 100 mg ASA per day proved to be selective: comparing the serum levels before and after treatment, a significant decrease of TXB2 concentration was found without changes in the concentration of 6-keto-prostaglandin-F1 alpha. Evaluating MAI and the value of dysaggregation might reflect ineffectiveness of antiplatelet therapy in patients not responding to a daily dose of 100 mg of ASA. For these patients the increase of the daily dose of ASA, or changing to another antiplatelet drug might be recommended.
authors.affiliation: Debreceni Orvostudományi Egyetem Ideg- és Elmegyógyászati Klinika.
authors.forename: L
authors.initials: L
authors.lastname: Oláh
authors.forename: M
authors.initials: M
authors.lastname: Misz
authors.forename: D
authors.initials: D
authors.lastname: Bereczki
authors.forename: I
authors.initials: I
authors.lastname: Fekete
authors.forename: J E
authors.initials: JE
authors.lastname: Bordánné
authors.forename: E I
authors.initials: EI
authors.lastname: Takács
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D002545:Brain Ischemia / Q000097:blood / Q000150:complications*; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011460:Prostaglandins F / Q000097:blood; D013928:Thromboxane A2 / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D010975:Platelet Aggregation Inhibitors; D011460:Prostaglandins F; D013929:Thromboxane B2; D013928:Thromboxane A2; D001241:Aspirin
vernacular_title: Kis dózisú acetil-szalicilát hatásosan gátolja a thrombocytaaggregatiót ischaemiás stroke után.